Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol 2024; 16(10): 1158-1168 [PMID: 39474576 DOI: 10.4254/wjh.v16.i10.1158]
Corresponding Author of This Article
Ming-Hui Li, MD, PhD, Chief Doctor, Professor, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Oct 27, 2024; 16(10): 1158-1168 Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1158
Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients
Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang, Ming-Hui Li
Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang, Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, Beijing 100015, China
Co-first authors: Wei-Hua Cao and Ya-Qin Zhang.
Author contributions: Li MH conceived the idea for the manuscript; Cao WH, Zhang YQ, and Li MH reviewed the literature and drafted the manuscript; Li XX and Zhang ZY reviewed the literature and proofread the manuscript.
Supported byThe National Key Research and Development Program, No. 2022YFC2603500 and No. 2022YFC2603505; Beijing Municipal Health Commission High-Level Public Health Technical Personnel Construction Project, No. Discipline leader-03-26; The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority, No. XXZ0302; The Capital Health Research and Development of Special Public Health Project, No. 2022-1-2172; and Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support, No. XMLX 202127.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Hui Li, MD, PhD, Chief Doctor, Professor, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Received: June 18, 2024 Revised: August 28, 2024 Accepted: September 19, 2024 Published online: October 27, 2024 Processing time: 124 Days and 12.3 Hours
Core Tip
Core Tip: Hepatitis B virus (HBV) infection interacts with the tumor microenvironment (TME) through a highly complex and intertwined signaling pathway, which results in a special TME in hepatocellular carcinoma (HCC). Due to changes in the TME, tumor cells can evade immune surveillance by inhibiting tumor-specific T cell function through CTLA-4 and programmed cell death 1 (PD-1)/PD ligand 1. Interferons, as a class of immune factors with strong biological activity, can improve the TME of HBV-HCC through various pathways. Currently, the systematic treatment of HCC has gradually come out of the dilemma. In addition to the continuous emergence of new multi-target anti-vascular tyrosine kinase inhibitor drugs, immune checkpoint inhibitors have opened up a new avenue for the systematic treatment of HCC. Since the disease characteristics of patients included in global clinical studies are different from those of Chinese patients, whether a group of HCC patients with HBV background and poor prognosis in China can also benefit from immunotherapy is an issue of wide concern.
